Cargando…
Novel Therapeutic Targets in Depression and Anxiety: Antioxidants as a Candidate Treatment
There is growing evidence that the imbalance between oxidative stress and the antioxidant defense system may be associated with the development neuropsychiatric disorders, such as depression and anxiety. Major depression and anxiety are presently correlated with a lowered total antioxidant state and...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bentham Science Publishers
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3964743/ https://www.ncbi.nlm.nih.gov/pubmed/24669206 http://dx.doi.org/10.2174/1570159X11666131120231448 |
_version_ | 1782479234659254272 |
---|---|
author | Xu, Ying Wang, Chuang Klabnik, Jonathan J O’Donnell, James M |
author_facet | Xu, Ying Wang, Chuang Klabnik, Jonathan J O’Donnell, James M |
author_sort | Xu, Ying |
collection | PubMed |
description | There is growing evidence that the imbalance between oxidative stress and the antioxidant defense system may be associated with the development neuropsychiatric disorders, such as depression and anxiety. Major depression and anxiety are presently correlated with a lowered total antioxidant state and by an activated oxidative stress (OS) pathway. The classical antidepressants may produce therapeutic effects other than regulation of monoamines by increasing the antioxidant levels and normalizing the damage caused by OS processes. This chapter provides an overview of recent work on oxidative stress markers in the animal models of depression and anxiety, as well as patients with the aforementioned mood disorders. It is well documented that antioxidants can remove the reactive oxygen species (ROS) and reactive nitrogen species (RNS) through scavenging radicals and suppressing the OS pathway, which further protect against neuronal damage caused oxidative or nitrosative stress sources in the brain, hopefully resulting in remission of depression or anxiety symptoms. The functional understanding of the relationship between oxidative stress and depression and anxiety may pave the way for discovery of novel targets for treatment of neuropsychiatric disorders. |
format | Online Article Text |
id | pubmed-3964743 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Bentham Science Publishers |
record_format | MEDLINE/PubMed |
spelling | pubmed-39647432014-09-01 Novel Therapeutic Targets in Depression and Anxiety: Antioxidants as a Candidate Treatment Xu, Ying Wang, Chuang Klabnik, Jonathan J O’Donnell, James M Curr Neuropharmacol Article There is growing evidence that the imbalance between oxidative stress and the antioxidant defense system may be associated with the development neuropsychiatric disorders, such as depression and anxiety. Major depression and anxiety are presently correlated with a lowered total antioxidant state and by an activated oxidative stress (OS) pathway. The classical antidepressants may produce therapeutic effects other than regulation of monoamines by increasing the antioxidant levels and normalizing the damage caused by OS processes. This chapter provides an overview of recent work on oxidative stress markers in the animal models of depression and anxiety, as well as patients with the aforementioned mood disorders. It is well documented that antioxidants can remove the reactive oxygen species (ROS) and reactive nitrogen species (RNS) through scavenging radicals and suppressing the OS pathway, which further protect against neuronal damage caused oxidative or nitrosative stress sources in the brain, hopefully resulting in remission of depression or anxiety symptoms. The functional understanding of the relationship between oxidative stress and depression and anxiety may pave the way for discovery of novel targets for treatment of neuropsychiatric disorders. Bentham Science Publishers 2014-03 2014-03 /pmc/articles/PMC3964743/ /pubmed/24669206 http://dx.doi.org/10.2174/1570159X11666131120231448 Text en ©2014 Bentham Science Publishers http://creativecommons.org/licenses/by-nc/3.0/ This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited. |
spellingShingle | Article Xu, Ying Wang, Chuang Klabnik, Jonathan J O’Donnell, James M Novel Therapeutic Targets in Depression and Anxiety: Antioxidants as a Candidate Treatment |
title | Novel Therapeutic Targets in Depression and Anxiety: Antioxidants as a Candidate Treatment |
title_full | Novel Therapeutic Targets in Depression and Anxiety: Antioxidants as a Candidate Treatment |
title_fullStr | Novel Therapeutic Targets in Depression and Anxiety: Antioxidants as a Candidate Treatment |
title_full_unstemmed | Novel Therapeutic Targets in Depression and Anxiety: Antioxidants as a Candidate Treatment |
title_short | Novel Therapeutic Targets in Depression and Anxiety: Antioxidants as a Candidate Treatment |
title_sort | novel therapeutic targets in depression and anxiety: antioxidants as a candidate treatment |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3964743/ https://www.ncbi.nlm.nih.gov/pubmed/24669206 http://dx.doi.org/10.2174/1570159X11666131120231448 |
work_keys_str_mv | AT xuying noveltherapeutictargetsindepressionandanxietyantioxidantsasacandidatetreatment AT wangchuang noveltherapeutictargetsindepressionandanxietyantioxidantsasacandidatetreatment AT klabnikjonathanj noveltherapeutictargetsindepressionandanxietyantioxidantsasacandidatetreatment AT odonnelljamesm noveltherapeutictargetsindepressionandanxietyantioxidantsasacandidatetreatment |